ARTICLE FROM KACTUS
Article: c-MET: A Key Target in Cancer Therapy Research
Laruen He from KACTUS has recently published an insightful overview on the hepatocyte growth factor (HGF)/c-MET signaling axis. While this pathway plays a critical role in early embryonic development and organ regeneration, its pathological activation can promote tumor growth and metastasis. For researchers developing novel targeted therapeutics, utilizing native-conformation c-MET proteins is essential to successfully discover functional antibodies and overcome drug resistance.
What is c-MET and how does it function?
c-MET is a receptor tyrosine kinase (RTK) that is initially synthesized as a single-chain precursor protein. Following cleavage, it converts into a mature heterodimer composed of an extracellular α-chain and a single-pass transmembrane β-chain.
- The extracellular region contains a SEMA domain, a PSI domain, and four IPT domains.
- The intracellular region comprises a tyrosine kinase (TK) domain and a multifunctional docking site that regulates downstream signal transduction.
When HGF binds to c-MET, it induces homodimerization and trans-phosphorylation. This activates pathways like Ras-MAPK/ERK and PI3K-Akt, driving cell proliferation and survival.
Why is c-MET a critical target in oncology?
In metastatic or drug-resistant cancers, the regulatory control of c-MET is often compromised. This results in oncogenic activation through either HGF-dependent hyper-stimulation or HGF-independent pathways, such as MET gene amplification.
Notably, c-MET amplification serves as a bypass mechanism for tumors. It occurs in 5-22% of non-small cell lung cancer (NSCLC) tumors that develop resistance to EGFR tyrosine kinase inhibitors (TKIs), making it a highly relevant target for combination therapies and bispecific antibodies.
What are the therapeutic research strategies targeting c-MET?
The therapeutic research landscape for c-MET is advancing rapidly, particularly through the use of antibody-drug conjugates (ADCs) and bispecific antibodies to overcome tumor resistance.
-
Antibody-Drug Conjugates (ADCs): Strategy involves designing ADCs that specifically target the c-MET SEMA domain. This approach blocks native HGF binding while delivering targeted cytotoxic payloads to c-MET-overexpressing tumor cells.
-
Bispecific Antibodies: Another major development is the engineering of bispecific antibodies that simultaneously target the extracellular domains of both EGFR and c-MET. This dual-targeting mechanism is highly effective at neutralizing tumors that have developed resistance to standard EGFR inhibitors.
How do KACTUS c-MET proteins support preclinical research?
As the development of ADCs and bispecifics evolves, the success of lead discovery depends heavily on the structural integrity of the target antigen. KACTUS offers a comprehensive catalog of high-purity c-MET proteins tailored to these exact applications:
- Human HGF R/c-MET Protein (His Tag): (Cat# MET-HM10D, MET-HM101)
- Human HGF R/c-MET SEMA Domain Protein (His Tag): (Cat# MET-HM105)
- Mouse and Cynomolgus c-MET Proteins: (Cat# MET-MM101, MET-CM101)
The bioactivity of these products is thoroughly evaluated using reciprocal validation. They undergo rigorous ELISA, SPR, and BLI testing to ensure high-affinity binding. By prioritizing native conformations and strictly controlling endotoxin levels, these reagents provide the reliability necessary for rigorous preclinical studies.
*All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.
LAB-A-PORTER: Your Local Partner for Oncology Research Support in Hong Kong
Bridge the gap in your preclinical studies with LAB-A-PORTER:
- Official Source: LAB-A-PORTER is the proud distributor of KACTUS in Hong Kong.
- Advanced Tools: LAB-A-PORTER provides essential preclinical research reagents, including high-quality KACTUS recombinant c-MET proteins and specific domains (such as SEMA and IPT).
- Streamlined Access: Order Kactus high-purity antigens from LAB-A-PORTER in Hong Kong for dedicated local support.
- Complete Solutions: Order a comprehensive range of solid tumor research targets from LAB-A-PORTER in Hong Kong to fully equip your laboratory.
Ready to elevate your next solid tumor research projects? Contact dolly@lab-a-porter.com or simply fill in an online to request a quotation.
ABOUT KACTUS
Provides quality recombinant proteins and enzymes that accelerate therapeutic development
Founded in 2018, KACTUS is a leading manufacturer of recombinant proteins and enzymes, providing both off-the-shelf products and custom protein services. Their extensive catalog includes over 3,000 recombinant proteins, featuring antibody drug targets, cytokines, transmembrane proteins, MHC monomers and tetramers, immune checkpoint proteins, biotinylated proteins, and more. They also offer AAV titration ELISA kits, GMP-grade gene editing enzymes, and other GMP enzymes. All their products undergo rigorous testing for purity and bioactivity to ensure quality performance and consistency. KACTUS is ISO 13485:2016 certified and operates state-of-the-art facilities, including a 10,000 sq. meter GMP-grade manufacturing site.